Compare Repligen Corporation Common Stock (RGEN) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Vistra Corp — how do they compare? Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B), while Vistra Corp trades at $148.75 (market cap $54.49B). The key difference: Vistra Corp is far larger — about 4.9× Repligen Corporation Common Stock's market cap, and Vistra Corp pays a 0.57% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Vistra Corp for 33 Days on average.
| RGEN | VST | |
|---|---|---|
Market Cap | $11.14B | $54.49B |
Volume | 1,259,263 | 5,289,982 |
Sector | Health | Utilities |
52-Week High | $194.57 | $210.85 |
52-Week Low | $102.87 | $134.71 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $11.02B | $76.43B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Vistra Corp (VST) trades at $162.36, up 2.68% with strong institutional support and bullish technical indicators. The stock shows impressive profitability with 75.73% ROE and 11.55% net margin, though recent earnings were mixed with Q1 beat but Q2 miss. Recent developments include a $4.2 billion government loan for nuclear expansion and a 20-year power deal with New Era Energy, positioning VST to capitalize on AI-driven electricity demand.
Vistra presents significant upside potential with a $215.23 consensus price target (32.5% upside) and 91.3% buy ratings. The company benefits from nuclear power expansion and AI infrastructure demand, though risks include execution of growth initiatives and energy market volatility. Current valuation at 27.38 P/E appears reasonable given growth prospects in the power generation sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
